MSC 2021 Virtual E-Abstract

2021 ◽  
Vol 3 (3) ◽  
pp. 37-42
Author(s):  
Malaysian Stroke Conference
Keyword(s):  
Growth Hormone ◽  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Healthcare Providers ◽  
Hormone Deficiency ◽  
Therapeutic Effects ◽  
Diagnostic Dilemma ◽  
Brain Recovery ◽  
Stroke Thrombolysis

1. Factors Influencing The Uptake Of Stroke Thrombolysis In Malaysia: A Case Study From The Healthcare Providers’ Perspective.2. Growth Hormone And Ischemic Stroke: Focus On Growth Hormone Deficiency And Therapeutic Effects Of Growth Hormone On Brain Recovery.3. Predictors Of Post-Thrombolysis Intracerebral Haemorrhage In Patients With Acute Ischemic Stroke.4. Predictors of Mortality In Thrombolysed Acute Ischemic Stroke Patients of Seberang Jaya Hospital.5. Bilateral Dejerine Syndrome: A Case Report with Diagnostic Dilemma.6. Outcome Of Ischemic Stroke Thrombolysis Treatment In Seberang Jaya Hospital, A Single Center 9 Years Review: 2012-2020.

scholarly journals Cerebral endothelial cell-derived small extracellular vesicles enhance neurovascular function and neurological recovery in rat acute ischemic stroke models of mechanical thrombectomy and embolic stroke treatment with tPA

2021 ◽  
pp. 0271678X2199298
Author(s):  
Chao Li ◽  
Chunyang Wang ◽  
Yi Zhang ◽  
Owais K Alsrouji ◽  
Alex B Chebl ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Extracellular Vesicles ◽  
Mechanical Thrombectomy ◽  
Infarct Volume ◽  
Artery Occlusion ◽  
Therapeutic Effects ◽  
Vessel Occlusion ◽  
Healthy Human ◽  
Stroke Treatment

Treatment of patients with cerebral large vessel occlusion with thrombectomy and tissue plasminogen activator (tPA) leads to incomplete reperfusion. Using rat models of embolic and transient middle cerebral artery occlusion (eMCAO and tMCAO), we investigated the effect on stroke outcomes of small extracellular vesicles (sEVs) derived from rat cerebral endothelial cells (CEC-sEVs) in combination with tPA (CEC-sEVs/tPA) as a treatment of eMCAO and tMCAO in rat. The effect of sEVs derived from clots acquired from patients who had undergone mechanical thrombectomy on healthy human CEC permeability was also evaluated. CEC-sEVs/tPA administered 4 h after eMCAO reduced infarct volume by ∼36%, increased recanalization of the occluded MCA, enhanced cerebral blood flow (CBF), and reduced blood-brain barrier (BBB) leakage. Treatment with CEC-sEVs given upon reperfusion after 2 h tMCAO significantly reduced infarct volume by ∼43%, and neurological outcomes were improved in both CEC-sEVs treated models. CEC-sEVs/tPA reduced a network of microRNAs (miRs) and proteins that mediate thrombosis, coagulation, and inflammation. Patient-clot derived sEVs increased CEC permeability, which was reduced by CEC-sEVs. CEC-sEV mediated suppression of a network of pro-thrombotic, -coagulant, and -inflammatory miRs and proteins likely contribute to therapeutic effects. Thus, CEC-sEVs have a therapeutic effect on acute ischemic stroke by reducing neurovascular damage.

Should Tenecteplase be Given in Clinical Practice for Acute Ischemic Stroke Thrombolysis?

Stroke ◽  
2021 ◽  
Author(s):  
Jukka Putaala ◽  
Jeffrey L. Saver ◽  
May Nour ◽  
Dawn Kleindorfer ◽  
Mollie McDermott ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Clinical Practice ◽  
Acute Ischemic Stroke ◽  
Stroke Thrombolysis

scholarly journals New standardized nursing cooperation workflow to reduce stroke thrombolysis delays in patients with acute ischemic stroke

2017 ◽  
Vol Volume 13 ◽  
pp. 1215-1220 ◽  
Author(s):  
Yan Zhou ◽  
Zhuojun Xu ◽  
Jiali Liao ◽  
Fangming Feng ◽  
Lai Men ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Stroke Thrombolysis

Possible growth hormone deficiency: a case study

2010 ◽  
Vol 18 (8) ◽  
pp. 22-23
Author(s):  
Raoul Chandrasakera
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Deficiency ◽  
Hormone Deficiency

Abstract 10: Neuroendocrine Dysfunction and Functional Disability Following Stroke

Stroke ◽  
2017 ◽  
Vol 48 (suppl_1) ◽  
Author(s):  
Lisa A Kreber ◽  
Charan K Singh
Keyword(s):  
Growth Hormone ◽  
Ischemic Stroke ◽  
Activities Of Daily Living ◽  
Daily Living ◽  
Independent Living ◽  
Functional Disability ◽  
Rating Scale ◽  
Hormone Deficiency ◽  
Stroke Patients ◽  
Disability Rating Scale

Comprehensive studies of the incidence of neuroendocrine dysfunction following stroke are lacking. The objectives of this study were to determine the incidence of neuroendocrine dysfunction in patients with stroke and to determine if growth hormone deficiency (GHD) contributes to disability following stroke. Hormones were assessed in 130 patients with stroke (ischemic: n=65; hemorrhagic: n=65; M time since stroke=155 days; men=81; M age = 52). TSH, T3, T4, follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol, testosterone, cortisol, and insulin-like growth factor-1 were assessed. All patients underwent glucagon stimulation testing (GST) to assess growth hormone (GH). Patients were then classified as having severe GHD, moderate GHD or normal GH based on the results of the GST. Functional disability was assessed with the Disability Rating Scale, Independent Living Scale (ILS), and the Mayo-Portland Adaptability Inventory-IV. The majority of stroke patients had GHD (30% severe; 29% moderate). Patients with ischemic stroke had a higher prevalence of GHD (34% severe; 33% moderate) compared to patients with hemorrhagic stroke (26% severe; 23% moderate). The severe GHD group had significantly lower levels of FSH than the moderate GHD and normal GH groups (p<0.01). The moderate GHD group had significantly lower levels of LH than the severe GHD and normal GH groups (p<0.05) and significantly lower levels of T3 than the severe GHD and normal GH groups (p<0.05). The severe GHD group performed worse on the Activities of Daily Living and Behavior subscales of the ILS than the moderate GHD and normal GH groups (p<0.05). GHD was more prevalent in patients with ischemic stroke, indicating that type of stroke may influence neuroendocrine functioning. Additionally, FSH, LH and T3 were lower in patients with GHD than in patients with normal levels of GH. The implications of these findings suggest that routine, comprehensive neuroendocrine testing may be warranted in individuals who have sustained a stroke. Patients with GHD were more functionally disabled in their ability to perform activities of daily living and to engage in socially appropriate behavior. These findings suggest that hormone deficiencies can influence disability post-stroke.

Safety and Efficacy Assessment of Chungpyesagan-tang for Acute Ischemic Stroke

2003 ◽  
Vol 31 (02) ◽  
pp. 181-190 ◽  
Author(s):  
Woo Sang Jung ◽  
Dong Jun Choi ◽  
Ki Ho Cho ◽  
Kyung Sup Lee ◽  
Sang Kwan Moon ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Treatment Group ◽  
Medical Treatment ◽  
Acute Ischemic Stroke ◽  
Onset Time ◽  
Therapeutic Effects ◽  
Clinical Safety ◽  
Safety And Efficacy ◽  
Efficacy Assessment ◽  
Herbal Formulations

Chungpyesagan-tang is one of the most well-known traditional herbal formulations frequently used for treatment of acute stroke in Korea. Therefore, this study aims to assess the clinical safety and efficacy of Chungpyesagan-tang on acute ischemic stroke. We recruited acute cerebral infarction subjects within 1 week after onset time. Then, we prescribed Chungpyesagan-tang to an Oriental medical treatment group (OM-group) for 2 weeks and enrolled a Western medical treatment group (WM-group) which received only Western biomedical care as a control. In this study, the OM-group was composed of 75 subjects. However, 14 of them dropped out, as two had progressive stroke while 12 complained of diarrhea. Thus, 61 cases were included in the analysis and compared to the 76 cases of the WM-group. The improvement of OM-group was better than that of the WM-group according to the National Institute of Health Stroke Scale (NIHSS), but not by the Modified Barthel Index (MBI). There were no definite abnormalities on laboratory safety assessment. Therefore, we suggest that Chungpyesagan-tang may have therapeutic effects, acting to reduce the severity of stroke and improving functional recovery without definite hepatic or renal toxicity when given for the first 2 weeks after a stroke.

Sign in / Sign up

Export Citation Format

Share Document